Hospital
Wayne General Hospital
Wayne General Hospital was paid $10.88M by Medicaid between Jan 2018 and Dec 2024, across 176 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoWAYNE GENERAL HOSPITAL
WAYNESBORO, MS 39367
WAYNESBORO, MS 39367
33aNPI1679559983assigned 12/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.88M
24GClaims361,825
24DCodes billed176
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#34 of 77
Median peer was paid$8.23M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 51,157 | $1.64M | |
| 2019 | 49,830 | $1.77M | |
| 2020 | 41,970 | $1.37M | |
| 2021 | 51,428 | $1.65M | |
| 2022 | 66,586 | $1.88M | |
| 2023 | 62,282 | $1.61M | |
| 2024incomplete | 38,572 | $961K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 17,812 | 14,143 | $2.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 11,200 | 8,750 | $1.87M |
| G0378 | Hospital observation service, per hour | 8.2% | 3,898 | 2,553 | $896K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.9% | 3,858 | 2,672 | $643K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.7% | 5,760 | 3,797 | $406K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.0% | 10,540 | 6,975 | $331K |
| A0425 | Ground mileage, per statute mile | 2.8% | 4,418 | 2,414 | $308K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.8% | 4,387 | 2,457 | $301K |
| 71045 | Radiologic examination, chest; single view | 2.7% | 8,766 | 6,392 | $289K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.3% | 13,019 | 2,706 | $249K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 1,286 | 1,040 | $198K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 4,298 | 814 | $191K |
164 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 9,343 | $160K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 4,229 | $159K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 3,348 | $143K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 3,493 | $142K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 3,165 | $130K |
| 80053 | Comprehensive metabolic panel | 1.1% | 19,776 | $123K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 24,234 | $109K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,366 | $96K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,363 | $92K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 2,679 | $90K |
| 86900 | <1% | 1,506 | $84K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 702 | $78K |
| 87428 | <1% | 1,581 | $73K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 30,043 | $65K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 384 | $64K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,538 | $63K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,268 | $62K |
| 74018 | <1% | 1,474 | $59K | |
| 97161 | <1% | 1,646 | $56K | |
| 84484 | <1% | 7,645 | $53K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,767 | $47K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,757 | $47K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 202 | $47K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,036 | $46K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 523 | $45K |
| 86850 | <1% | 1,447 | $38K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,047 | $37K |
| 83880 | <1% | 2,134 | $37K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,092 | $33K |
| 80061 | Lipid panel | <1% | 4,453 | $33K |
| 82553 | <1% | 4,682 | $32K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 869 | $32K |
| 87430 | <1% | 2,350 | $29K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,074 | $29K |
| 87088 | <1% | 4,757 | $27K | |
| 86901 | <1% | 1,265 | $23K | |
| 82550 | <1% | 5,027 | $22K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,844 | $22K |
| 81001 | <1% | 11,850 | $22K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 276 | $21K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 302 | $19K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 78 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,374 | $19K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 593 | $19K |
| 59025 | Fetal non-stress test | <1% | 180 | $18K |
| 73562 | <1% | 555 | $18K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 95 | $18K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 382 | $17K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 831 | $17K |
| 87186 | <1% | 2,538 | $15K | |
| 87077 | <1% | 2,412 | $15K | |
| 87081 | <1% | 2,507 | $14K | |
| 73630 | <1% | 372 | $13K | |
| 82803 | <1% | 741 | $11K | |
| 81025 | <1% | 1,833 | $10K | |
| 83690 | <1% | 2,255 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 607 | $10K |
| 83605 | <1% | 1,673 | $9K | |
| 59050 | <1% | 263 | $8K | |
| 73610 | <1% | 193 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,550 | $8K |
| 96367 | <1% | 297 | $8K | |
| 84439 | <1% | 1,521 | $7K | |
| 87340 | <1% | 889 | $7K | |
| 87807 | <1% | 531 | $6K | |
| 85610 | <1% | 2,987 | $6K | |
| 82150 | <1% | 1,205 | $6K | |
| 85730 | <1% | 1,759 | $6K | |
| 73030 | <1% | 183 | $6K | |
| 86592 | <1% | 1,636 | $5K | |
| 86317 | <1% | 394 | $5K | |
| 85379 | <1% | 669 | $5K | |
| 84703 | <1% | 858 | $4K | |
| 82607 | <1% | 625 | $4K | |
| 94799 | <1% | 135 | $4K | |
| 87653 | <1% | 145 | $4K | |
| 86703 | <1% | 323 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 277 | $4K |
| 83735 | <1% | 1,434 | $4K | |
| 87070 | <1% | 703 | $4K | |
| 85018 | <1% | 2,130 | $4K | |
| 87040 | <1% | 651 | $3K | |
| 85014 | <1% | 2,015 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,214 | $3K |
| 97597 | <1% | 56 | $3K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 900 | $3K |
| 73130 | <1% | 69 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 40 | $2K |
| 83540 | <1% | 556 | $2K | |
| 82947 | <1% | 784 | $2K | |
| 84702 | <1% | 209 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 41 | $2K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 18 | $2K |
| 84466 | <1% | 197 | $2K | |
| 82077 | <1% | 278 | $2K | |
| 72110 | <1% | 33 | $2K | |
| 82728 | <1% | 171 | $1K | |
| 73502 | <1% | 35 | $1K | |
| 83655 | <1% | 128 | $1K | |
| 86677 | <1% | 107 | $1K | |
| 83550 | <1% | 195 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,952 | $953.57 |
| 81015 | <1% | 1,321 | $895.12 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 29 | $818.53 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 16 | $629.28 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 15 | $548.77 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,549 | $539.03 |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 17 | $537.57 |
| 82570 | <1% | 222 | $506.38 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 40 | $503.92 |
| 82746 | <1% | 54 | $474.81 | |
| 82948 | <1% | 444 | $437.86 | |
| 94760 | <1% | 1,753 | $361.30 | |
| 80076 | <1% | 55 | $347.04 | |
| 86140 | <1% | 78 | $268.22 | |
| 85027 | <1% | 85 | $221.16 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,701 | $204.92 |
| 82043 | <1% | 82 | $176.83 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 14 | $175.16 |
| 86762 | <1% | 12 | $155.40 | |
| 85660 | <1% | 31 | $145.28 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,319 | $121.22 |
| 84550 | <1% | 30 | $118.50 | |
| 85651 | <1% | 47 | $110.46 | |
| 84100 | <1% | 49 | $93.94 | |
| 84156 | <1% | 38 | $84.93 | |
| 36000 | <1% | 1,349 | $73.39 | |
| 82248 | <1% | 13 | $72.73 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,395 | $71.24 |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 694 | $54.85 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 28 | $52.14 |
| 82950 | <1% | 13 | $50.73 | |
| 85007 | <1% | 57 | $34.20 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 64 | $31.62 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 660 | $27.60 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,348 | $24.80 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 599 | $7.92 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 492 | $4.33 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,639 | $0.78 |
| 96376 | <1% | 496 | $0.15 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 375 | $0.00 |
| J3490 | Unclassified drugs | 0% | 1,928 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 61 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 206 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 47 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 15 | $0.00 |
| 99292 | 0% | 36 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 18 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 14 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 105 | $0.00 |
| 80320 | 0% | 16 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 15 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 25 | $0.00 |
| 84145 | 0% | 854 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 215 | $0.00 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 1,135 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 284 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 974 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 58 | $0.00 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 224 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 81 | $0.00 |
| 90715 | 0% | 14 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 98 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWADDELL, KATHY (ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Wayne General Hospital | Waynesboro, MS | $3.85M |
| Wayne General Hospital | Waynesboro, MS | $1.47M |
| Wayne General Hospital | Waynesboro, MS | $1.13M |
| Wayne General Hospital | Waynesboro, MS | $102K |
| Wayne General Hospsital | Waynesboro, MS | $10K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.